智通财经APP讯，金活医药集团(01110)公布，于2026年1月22日，公司的全资附属公司金活医药(BVI)就建议收购事项与拟定卖方及担保人订立谅解备忘录。预计代价将以现金支付。担保人同意就拟定卖方履行其于谅解备忘录项下的责任提供担保。
受签立买卖协议及当中所述调整机制(如有)所规限，总代价须包括：(i)基本购买价6643.68万港元，其中4150万港元涉及目标公司的相关业务及生产设备(车辆除外)，2493.68万港元涉及地产物业;(ii)目标公司设备(不包括任何车辆)于完成时的净账面值;及(iii)于完成时的营运资金净额(即应收账款与存货总和减应付账款)，惟须根据依照香港财务报告准则编制的经审核账目作出完成后调整。自签订谅解备忘录起五个营业日内，金活医药(BVI)将向拟定卖方支付按金约332.18万港元。
公告称，目标公司为一间于香港注册成立的公司，主要从事药品生产及销售，并于地产物业内进行营运。董事认为，倘建议收购事项得以落实，将使集团能够扩大其于香港医药行业的版图，获得包括地产物业在内的宝贵制造资产，并透过产品分销及营运规模的协同效应，促进集团的海内外业务发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.